Transfemoral Tricuspid Valve Repair Using a Percutaneous Mitral Valve Repair System

Schöfer, Joachim; Tiburtius, Claudia; Hammerstingl, Christoph; Dickhaut, Per-Olof; Witt, Julian; Hansen, Lorenz; Rieß, Friedrich-Christian; Bijuklic, Klaudija

doi:10.1016/j.jacc.2015.11.047

Cited by 33 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Trialign™ system (Mitralign Inc.) is designed to perform a percutaneous suture annuloplasty of the TV, replicating the surgical bicuspidation technique, which is based on reducing annular dilatation and improving TV competency by plication of the posterior tricuspid annulus (see Figure 3B). 12,13 With the Trialign device, the posterior leaflet is plicated by means of a pair of pledgeted sutures, which are implanted transanular from the ventricle to the atrium. Through right jugular access, the system is advanced in the right atrium, and then across the TV into the RV on fluoroscopic and TEE guidance.…”

Section: The Trialign™ Systemmentioning

confidence: 99%

Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies

Taramasso

Calen

Guidotti

et al. 2017

Interventional Cardiology Review

View full text Add to dashboard Cite

Surgical treatment is the gold standard treatment of functional tricuspid regurgitation (FTR) but this carries high risks of morbidity and mortality. Percutaneous procedures are an attractive alternative to surgery for selected patients deemed to be high-risk surgical candidates. A number of tricuspid transcatheter devices have been developed to treat FTR, but at present, evidence of their efficacy and safety is scarce. Preliminary data have shown promising results, but ongoing and future studies will provide a clearer picture of the benefits of these new techniques.

show abstract

Section: The Trialign™ Systemmentioning

confidence: 99%

Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies

Taramasso

Calen

Guidotti

et al. 2017

Interventional Cardiology Review

View full text Add to dashboard Cite

show abstract

“…The first case reports of transcatheter edge-to-edge repair published in 2016 demonstrated its technical feasibility and procedural safety for patients with severe primary or secondary TR with a prohibitive operative risk. 28,29 Hammerstingl et al reported three consecutive patients treated successfully for significant TR in advanced stages of right heart failure and multiorgan damage. 30 Reduction of measured effective regurgitation orifice area (EROA) was observed in all the patients.…”

Section: Preliminary Experience Of Transcatheter Edge-to-edge Repairmentioning

confidence: 99%

Transcatheter Edge-to-edge Repair of Severe Tricuspid Regurgitation

Lin

Miura

Züber

et al. 2019

US Cardiology Review

View full text Add to dashboard Cite

Despite the increasing knowledge of the long-term adverse consequence of severe tricuspid regurgitation (TR), most patients with moderateto-severe TR are still treated conservatively because of the high risk of surgery. Percutaneous procedures have emerged as an attractive alternative treatment. Transcatheter edge-to-edge repair is a validated technique to treat mitral regurgitation. In recent years, the same concept has been applied to patients with TR and prohibitive operative risk. Early trials have shown feasibility and safety. More clinical experiences and long-term results are still being gathered. In this article, we provide an overview of transcatheter edge-to-edge repair and look at the current evidence and clinical results regarding procedure.

show abstract

“…Using edge-to-edge repair in between all three tricuspid commissures resulted in improvement in the TR and HF symptoms [ 26 ]. Furthermore, successful transfemoral implantations have been reported [ 27 , 28 ].…”

Section: Percutaneous Tricuspid Valve Repairmentioning

confidence: 99%

The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure

Nijenhuis

Sanchís²,

Heyden

et al. 2017

Neth Heart J

View full text Add to dashboard Cite

Heart failure has a high prevalence in the general population. Morbidity and mortality of heart failure patients remain high, despite improvements in drug therapy, implantable cardioverter-defibrillators and cardiac resynchronisation therapy. New transcatheter implantable devices have been developed to improve the treatment of heart failure. There has been a rapid development of minimally invasive or transcatheter devices used in the treatment of heart failure associated with aortic and mitral valve disease and these devices are being incorporated into routine clinical practice at a fast rate. Several other new transcatheter structural heart interventions for chronic heart failure aimed at a variety of pathophysiologic approaches are currently being developed. In this review, we focus on devices used in the treatment of chronic heart failure by means of left ventricular remodelling, left atrial pressure reduction, tricuspid regurgitation reduction and neuromodulation. The clinical evaluations of these devices are early-stage evaluations of initial feasibility and safety studies and additional clinical evidence needs to be gathered in appropriately designed clinical trials.

show abstract

Transfemoral Tricuspid Valve Repair Using a Percutaneous Mitral Valve Repair System

Cited by 33 publications

References 3 publications

Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies

Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies

Transcatheter Edge-to-edge Repair of Severe Tricuspid Regurgitation

The last frontier: transcatheter devices for percutaneous or minimally invasive treatment of chronic heart failure

Contact Info

Product

Resources

About